Diego Serrano-Muñoz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Diego Serrano-Muñoz has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Julio Gómez-Soriano
Toledo Physiotherapy Research Group (GIFTO), Faculty of Physiotherapy and Nursing, Universidad de Castilla-La Mancha, 45071 Toledo, Spain
25 shared publications - Juan Avendaño-Coy
Toledo Physiotherapy Research Group (GIFTO), Faculty of Physiotherapy and Nursing, University of Castilla-La Mancha, 45071 Toledo, Spain
18 shared publications - Julian Taylor
Sensorimotor Function Group, Hospital Nacional de Parapléjicos (SESCAM), 45071 Toledo, Spain
17 shared publications Juan Avendaño-Coy
Toledo Physiotherapy Research Group (GIFTO), Faculty of Physiotherapy and Nursing of Toledo, Universidad de Castilla-La Mancha, Toledo, Spain
7 shared publicationsJulio Gómez-Soriano
Toledo Physiotherapy Research Group (GIFTO), Faculty of Physiotherapy and Nursing of Toledo, Universidad de Castilla-La Mancha, Toledo, Spain
7 shared publicationsDavid Martín-Caro Álvarez
Toledo Physiotherapy Research Group (GIFTO), Faculty of Physiotherapy and Nursing of Toledo, Universidad de Castilla-La Mancha, Toledo, Spain
6 shared publications
Latest Publications
- Open Access
Feasibility and Safety of Combined Robot-Assisted Gait Training and Transcutaneous Spinal Cord Stimulation in Pediatric Incomplete Spinal Cord Injury: A Case Series
Background/Objectives: Pediatric spinal cord injury (SCI) is a rare yet highly disabling condition associated with substantial functional and psychosocial impairments. Although robot-assisted gait training (RAGT) and transcutaneous spinal cord stimulation (tSCS) have independently demonstrated promising results, evidence regarding their combined use in pediatric SCI is limited. This study aimed primarily to assess the feasibility and safety of combining RAGT with tSCS in children with incomplete SCI, and secondarily to explore its effects on clinical outcomes. Methods: A case series study was conducted that included three pediatric participants (<18 years) with chronic incomplete SCI (AIS C–D). Participants completed five consecutive sessions of RAGT using a Lokomat device combined with tSCS applied at the lumbosacral level. Each session consisted of 30 min of gait training, including 20 min of concurrent electrical stimulation. Safety was assessed through adverse-event monitoring and pain evaluation. Clinical outcomes included gait speed (10MWT), trunk control (SATCo), lower-limb strength (LEMS), and spasticity (MAS). Results: Session adherence reached 100%. Skin erythema was the most frequently reported adverse event and showed a clear association with tSCS. All participants demonstrated improvements in gait speed, with two exceeding the minimal clinically important difference. Secondary results showed similar outcomes for spasticity, strength, and trunk control, with no clinically meaningful changes in any case. Conclusions: The combined application of RAGT and tSCS appears to be a feasible and safe intervention for children with incomplete SCI. Preliminary findings suggest potential benefits in gait speed, thereby supporting the need for further investigation with larger samples and controlled study designs.
Open AccessFeasibility and Safety of Combined Robot-Assisted Gait Training and Transcutaneous Spinal Cord Stimulation in Pediatric Incomplete Spinal Cord Injury: A Case Series
Background/Objectives: Pediatric spinal cord injury (SCI) is a rare yet highly disabling condition associated with substantial functional and psychosocial impairments. Although robot-assisted gait training (RAGT) and transcutaneous spinal cord stimulation (tSCS) have independently demonstrated promising results, evidence regarding their combined use in pediatric SCI is limited. This study aimed primarily to assess the feasibility and safety of combining RAGT with tSCS in children with incomplete SCI, and secondarily to explore its effects on clinical outcomes. Methods: A case series study was conducted that included three pediatric participants (<18 years) with chronic incomplete SCI (AIS C–D). Participants completed five consecutive sessions of RAGT using a Lokomat device combined with tSCS applied at the lumbosacral level. Each session consisted of 30 min of gait training, including 20 min of concurrent electrical stimulation. Safety was assessed through adverse-event monitoring and pain evaluation. Clinical outcomes included gait speed (10MWT), trunk control (SATCo), lower-limb strength (LEMS), and spasticity (MAS). Results: Session adherence reached 100%. Skin erythema was the most frequently reported adverse event and showed a clear association with tSCS. All participants demonstrated improvements in gait speed, with two exceeding the minimal clinically important difference. Secondary results showed similar outcomes for spasticity, strength, and trunk control, with no clinically meaningful changes in any case. Conclusions: The combined application of RAGT and tSCS appears to be a feasible and safe intervention for children with incomplete SCI. Preliminary findings suggest potential benefits in gait speed, thereby supporting the need for further investigation with larger samples and controlled study designs.
- 17 March 2026
- Published by Springer Nature in Spinal Cord
- Vol. 64 (4) , 303-316
Effectiveness of transcranial magnetic stimulation on gait and spasticity in people with spinal cord injury: a systematic review and meta-analysis
Study design Systematic review and meta-analysis. Objective To determine the effectiveness of transcranial magnetic stimulation (TMS) in improving gait velocity and spasticity in people with spinal cord injury (SCI). Setting Studies included in the review were conducted in various countries; the review was carried out in Spain. Methods A systematic review with meta-analysis was conducted by searching for randomized controlled trials published up to November 2024 comparing the application of TMS with a sham group. Outcome variables were gait velocity and spasticity, measured with the 10 m walking test and the Modified Ashworth Scale (MAS) respectively. PubMed, Cochrane Central Register of Controlled Trials, Web of Science, CINAHL and PEDro databases were consulted. Results Fourteen studies were included in the qualitative analysis and twelve in the quantitative analysis, involving 235 participants with SCI. No significant differences were detected for the effect of TMS on gait velocity (SMD = −0.71; 95%CI: −1.62 to 0.20). However, TMS produced a significant decrease in MAS compared to the control group (MD = −0.56 points; 95%CI: −0.82 to −0.30). Although the subgroup analysis based on the number of pulses showed no significant differences between applications of <1000 and ≥1000 pulses, the ≥1000 pulses subgroup showed significant differences (MD = −0.56 points; 95%CI: −0.83 to −0.30) favoring the experimental group, while the <1000 pulses subgroup showed no significant differences (MD = −0.35 points; 95%CI: −2.03 to 1.34). Conclusions TMS is effective in improving spasticity in people with SCI with low certainty of evidence. However, TMS has not demonstrated a significant effect on gait velocity, with very low certainty of evidence. Further studies comparing the number of pulses and their effectiveness are warranted to elucidate the findings of this meta-analysis.
- 17 March 2026
- Published by Springer Nature in Spinal Cord
- Vol. 64 (4) , 303-316
Effectiveness of transcranial magnetic stimulation on gait and spasticity in people with spinal cord injury: a systematic review and meta-analysis
Study design Systematic review and meta-analysis. Objective To determine the effectiveness of transcranial magnetic stimulation (TMS) in improving gait velocity and spasticity in people with spinal cord injury (SCI). Setting Studies included in the review were conducted in various countries; the review was carried out in Spain. Methods A systematic review with meta-analysis was conducted by searching for randomized controlled trials published up to November 2024 comparing the application of TMS with a sham group. Outcome variables were gait velocity and spasticity, measured with the 10 m walking test and the Modified Ashworth Scale (MAS) respectively. PubMed, Cochrane Central Register of Controlled Trials, Web of Science, CINAHL and PEDro databases were consulted. Results Fourteen studies were included in the qualitative analysis and twelve in the quantitative analysis, involving 235 participants with SCI. No significant differences were detected for the effect of TMS on gait velocity (SMD = −0.71; 95%CI: −1.62 to 0.20). However, TMS produced a significant decrease in MAS compared to the control group (MD = −0.56 points; 95%CI: −0.82 to −0.30). Although the subgroup analysis based on the number of pulses showed no significant differences between applications of <1000 and ≥1000 pulses, the ≥1000 pulses subgroup showed significant differences (MD = −0.56 points; 95%CI: −0.83 to −0.30) favoring the experimental group, while the <1000 pulses subgroup showed no significant differences (MD = −0.35 points; 95%CI: −2.03 to 1.34). Conclusions TMS is effective in improving spasticity in people with SCI with low certainty of evidence. However, TMS has not demonstrated a significant effect on gait velocity, with very low certainty of evidence. Further studies comparing the number of pulses and their effectiveness are warranted to elucidate the findings of this meta-analysis.
- Open Access
- 11 February 2025
- Published by Springer Nature in Journal of NeuroEngineering and Rehabilitation
- Vol. 22 (1) , 1-2
Correction: Selective nociceptive modulation using a novel prototype of transcutaneous kilohertz high-frequency alternating current stimulation: a crossover double-blind randomized sham-controlled trial
- 11 February 2025
- Published by Springer Nature in Journal of NeuroEngineering and Rehabilitation
- Vol. 22 (1) , 1-2
Open AccessCorrection: Selective nociceptive modulation using a novel prototype of transcutaneous kilohertz high-frequency alternating current stimulation: a crossover double-blind randomized sham-controlled trial
- Open Access
- 12 December 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (24) , 7566
Transcutaneous Kilohertz High-Frequency Alternating Current at 10 kHz for Upper-Limb Tremor in People with Parkinson’s Disease: A Double-Blind, Randomized, Crossover Study
Background/Objectives: Preclinical studies have evidenced a peripheral nerve blockade with kilohertz high-frequency alternating current (KHFAC) stimulation. It could have a potential effect on aberrant nerve hyperactivity, such as tremor in people with Parkinson’s disease (PwPD). The objective was to investigate the effects of transcutaneous KHFAC at 10 kHz compared with sham intervention on tremor modulation, upper limb motor function, and adverse events in PwPD. Methods: This randomized, double-blind, crossover trial included PwPD, who received transcutaneous KHFAC and sham interventions, within a 48 h washout period. Measurements were taken pre-intervention, during, immediately after, and 10 min post-intervention. The main outcomes were rest, postural, and kinetic tremor acceleration. Secondary outcomes were handgrip strength, nine-hole peg test (NHPT), movement onset time, and adverse events. Results: Sixteen PwPD were analyzed. Kinetic tremor diminished only in active treatment from baseline at post-intervention (−32.3% (SD 63.3); p = 0.03) and 10 min after intervention (−38.9% (SD 60.3); p = 0.03). Active treatment showed a greater reduction in kinetic tremor at post-treatment compared to sham (−58.7% SD 123; p = 0.055) close to reaching statistical significance. Only active intervention diminished movement onset time at post-intervention (−26.9% (SD 28.3); p = 0.04). Active intervention diminished handgrip strength compared to sham intervention during the stimulation (−6.6% (SD 10.0); p = 0.02). No relevant adverse effects were reported. Conclusions: KHFAC stimulation at 10 kHz appeared safe and showed potential benefits for reducing kinetic tremor in PwPD. The transient reduction in grip strength suggested an effect on alpha-motoneurons. However, further studies with larger sample sizes are necessary to confirm these findings.
- 12 December 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (24) , 7566
Open AccessTranscutaneous Kilohertz High-Frequency Alternating Current at 10 kHz for Upper-Limb Tremor in People with Parkinson’s Disease: A Double-Blind, Randomized, Crossover Study
Background/Objectives: Preclinical studies have evidenced a peripheral nerve blockade with kilohertz high-frequency alternating current (KHFAC) stimulation. It could have a potential effect on aberrant nerve hyperactivity, such as tremor in people with Parkinson’s disease (PwPD). The objective was to investigate the effects of transcutaneous KHFAC at 10 kHz compared with sham intervention on tremor modulation, upper limb motor function, and adverse events in PwPD. Methods: This randomized, double-blind, crossover trial included PwPD, who received transcutaneous KHFAC and sham interventions, within a 48 h washout period. Measurements were taken pre-intervention, during, immediately after, and 10 min post-intervention. The main outcomes were rest, postural, and kinetic tremor acceleration. Secondary outcomes were handgrip strength, nine-hole peg test (NHPT), movement onset time, and adverse events. Results: Sixteen PwPD were analyzed. Kinetic tremor diminished only in active treatment from baseline at post-intervention (−32.3% (SD 63.3); p = 0.03) and 10 min after intervention (−38.9% (SD 60.3); p = 0.03). Active treatment showed a greater reduction in kinetic tremor at post-treatment compared to sham (−58.7% SD 123; p = 0.055) close to reaching statistical significance. Only active intervention diminished movement onset time at post-intervention (−26.9% (SD 28.3); p = 0.04). Active intervention diminished handgrip strength compared to sham intervention during the stimulation (−6.6% (SD 10.0); p = 0.02). No relevant adverse effects were reported. Conclusions: KHFAC stimulation at 10 kHz appeared safe and showed potential benefits for reducing kinetic tremor in PwPD. The transient reduction in grip strength suggested an effect on alpha-motoneurons. However, further studies with larger sample sizes are necessary to confirm these findings.
- Open Access
- 15 November 2024
- Published by Springer Nature in Journal of NeuroEngineering and Rehabilitation
- Vol. 21 (1) , 1-12
Selective nociceptive modulation using a novel prototype of transcutaneous kilohertz high-frequency alternating current stimulation: a crossover double-blind randomized sham-controlled trial
Kilohertz high-frequency alternating current (KHFAC) stimulation has demonstrated to induce rapid and reversible nerve blocks without causing nerve damage. Previous studies have explored frequency-dependent effects using a transcutaneous approach in humans from 5 to 20 kHz. Nevertheless, its application in humans is limited by the lack of stimulators approved for frequencies above 20 kHz. Therefore, this study aimed to assess the effects and safety of transcutaneous KHFAC stimulation using a novel prototype stimulator, comparing interventions at 30, 40, and 50 kHz to sham stimulation on experimental pain, sensory, motor, and neurophysiological outcomes. A randomized, double-blind, sham-controlled crossover study involving 34 healthy participants was conducted. Four interventions (30, 40, 50 kHz, and sham) were administered, and stimulation was applied for 20 min to the median nerve of the non-dominant hand. A prototype stimulator capable of delivering frequencies between 1 and 50 kHz, with a maximum peak-to-peak output current intensity of 400 mA was designed. The intensity applied during the stimulation was below motor threshold, evoking a ‘strong but comfortable’ tingling sensation. Primary outcomes included heat pain threshold (HPT), pressure pain threshold (PPT), and adverse effects. The secondary outcomes included static two-point discrimination sensitivity, isometric pinch strength, and median sensory nerve action potential (SNAP). Compared with the sham stimulation, all the active interventions exhibited a significantly greater increase in the PPT during and immediately after the stimulation, while only a significant increase was observed at 40 kHz (4.1 N/cm2; 95%CI 0.3 to 7.9) at 15 min post-intervention. Compared to sham stimulation, the 40 kHz intervention had a significantly greater effect on the HPT at all time points, with the greatest difference (1.4 °C; 0.6 to 2.1) occurring immediately post-intervention. Adverse effects during active interventions included petechiae, erythema, and itching, which resolved at 24 h post-intervention. For secondary outcomes, only a significant reduction in the median SNAP velocity was observed in the sham stimulation group compared to the 50 kHz group. Active KHFAC stimulation, particularly at 40 kHz, delivered through a novel stimulator, effectively increased the PPT and HPT without affecting tactile or motor outcomes, inducing mild skin-related adverse effects. These findings have potential implications for people with pain-related pathologies. NCT05230836.
- 15 November 2024
- Published by Springer Nature in Journal of NeuroEngineering and Rehabilitation
- Vol. 21 (1) , 1-12
Open AccessSelective nociceptive modulation using a novel prototype of transcutaneous kilohertz high-frequency alternating current stimulation: a crossover double-blind randomized sham-controlled trial
Kilohertz high-frequency alternating current (KHFAC) stimulation has demonstrated to induce rapid and reversible nerve blocks without causing nerve damage. Previous studies have explored frequency-dependent effects using a transcutaneous approach in humans from 5 to 20 kHz. Nevertheless, its application in humans is limited by the lack of stimulators approved for frequencies above 20 kHz. Therefore, this study aimed to assess the effects and safety of transcutaneous KHFAC stimulation using a novel prototype stimulator, comparing interventions at 30, 40, and 50 kHz to sham stimulation on experimental pain, sensory, motor, and neurophysiological outcomes. A randomized, double-blind, sham-controlled crossover study involving 34 healthy participants was conducted. Four interventions (30, 40, 50 kHz, and sham) were administered, and stimulation was applied for 20 min to the median nerve of the non-dominant hand. A prototype stimulator capable of delivering frequencies between 1 and 50 kHz, with a maximum peak-to-peak output current intensity of 400 mA was designed. The intensity applied during the stimulation was below motor threshold, evoking a ‘strong but comfortable’ tingling sensation. Primary outcomes included heat pain threshold (HPT), pressure pain threshold (PPT), and adverse effects. The secondary outcomes included static two-point discrimination sensitivity, isometric pinch strength, and median sensory nerve action potential (SNAP). Compared with the sham stimulation, all the active interventions exhibited a significantly greater increase in the PPT during and immediately after the stimulation, while only a significant increase was observed at 40 kHz (4.1 N/cm2; 95%CI 0.3 to 7.9) at 15 min post-intervention. Compared to sham stimulation, the 40 kHz intervention had a significantly greater effect on the HPT at all time points, with the greatest difference (1.4 °C; 0.6 to 2.1) occurring immediately post-intervention. Adverse effects during active interventions included petechiae, erythema, and itching, which resolved at 24 h post-intervention. For secondary outcomes, only a significant reduction in the median SNAP velocity was observed in the sham stimulation group compared to the 50 kHz group. Active KHFAC stimulation, particularly at 40 kHz, delivered through a novel stimulator, effectively increased the PPT and HPT without affecting tactile or motor outcomes, inducing mild skin-related adverse effects. These findings have potential implications for people with pain-related pathologies. NCT05230836.
- 13 December 2023
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 103 (5) , 428-438
Efficacy of Transcranial Direct Current Stimulation on Pain Intensity and Functionality in Patients With Knee Osteoarthritis
Objective: The aim of the study is to investigate whether transcranial direct current stimulation is superior to control groups or other interventions for pain relief and improving functionality in knee osteoarthritis patients. Methods: PubMed, the Physiotherapy Evidence Database, the Cochrane Library, ProQuest, and Scopus databases were searched from inception to July 2022 to identify randomized clinical trials. The main outcomes were subjective perception of pain intensity measured either with the visual analog scale or with the numeric rating scale; and the functionality, assessed with the Western Ontario and McMaster Universities Osteoarthritis Index. As secondary outcomes, pressure pain threshold, conditioned pain modulation, and its safety were evaluated. Results: We identified 10 randomized clinical trials (634 participants). The results showed an important effect favoring transcranial direct current stimulation for pain relief (mean difference = −1.1 cm, 95% confident interval = −2.1 to −0.2) and for improving functionality (standardized mean difference = −0.6, 95% confident interval = −1.02 to −0.26). There was also a significant improvement in pressure pain threshold (mean difference = 0.9 Kgf/cm2, 95% confident interval = 0.1 to 1.6). The certainty of evidence according to Grades of Recommendation Assessment, Development and Evaluation was generally moderate. Conclusions: Our findings suggest that transcranial direct current stimulation is a safe treatment for reducing pain intensity, improving functionality, and the pressure pain thresholds in patients with knee osteoarthritis.
- 13 December 2023
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 103 (5) , 428-438
Efficacy of Transcranial Direct Current Stimulation on Pain Intensity and Functionality in Patients With Knee Osteoarthritis
Objective: The aim of the study is to investigate whether transcranial direct current stimulation is superior to control groups or other interventions for pain relief and improving functionality in knee osteoarthritis patients. Methods: PubMed, the Physiotherapy Evidence Database, the Cochrane Library, ProQuest, and Scopus databases were searched from inception to July 2022 to identify randomized clinical trials. The main outcomes were subjective perception of pain intensity measured either with the visual analog scale or with the numeric rating scale; and the functionality, assessed with the Western Ontario and McMaster Universities Osteoarthritis Index. As secondary outcomes, pressure pain threshold, conditioned pain modulation, and its safety were evaluated. Results: We identified 10 randomized clinical trials (634 participants). The results showed an important effect favoring transcranial direct current stimulation for pain relief (mean difference = −1.1 cm, 95% confident interval = −2.1 to −0.2) and for improving functionality (standardized mean difference = −0.6, 95% confident interval = −1.02 to −0.26). There was also a significant improvement in pressure pain threshold (mean difference = 0.9 Kgf/cm2, 95% confident interval = 0.1 to 1.6). The certainty of evidence according to Grades of Recommendation Assessment, Development and Evaluation was generally moderate. Conclusions: Our findings suggest that transcranial direct current stimulation is a safe treatment for reducing pain intensity, improving functionality, and the pressure pain thresholds in patients with knee osteoarthritis.
- 24 November 2023
- Published by Wolters Kluwer Health in Journal of Neurologic Physical Therapy
- Vol. 48 (2) , 66-74
Trans-Spinal Direct Current Stimulation in Neurological Disorders: A systematic review
Background and Purpose: Trans-spinal direct current stimulation (tsDCS) is a noninvasive stimulation technique that applies direct current stimulation over spinal levels. However, the effectiveness and feasibility of this stimulation are still unclear. This systematic review summarizes the effectiveness of tsDCS in clinical and neurophysiological outcomes in neurological patients, as well as its feasibility and safety. Methods: The search was conducted using the following databases: PEDro, Scopus, Web of Science, CINAHL, SPORTDiscus, and PubMed. The inclusion criteria were: Participants: people with central nervous system diseases; Interventions: tsDCS alone or in combination with locomotion training; Comparators: sham tsDCS, transcranial direct current stimulation, or locomotion training; Outcomes: clinical and neurophysiological measures; and Studies: randomized clinical trials. Results: Eight studies with a total of 143 subjects were included. Anodal tsDCS led to a reduction in hypertonia, neuropathic pain intensity, and balance deficits in people with hereditary spastic paraplegia, multiple sclerosis, and primary orthostatic tremor, respectively. In contrast, cathodal tsDCS only had positive effects on balance and tremor in people with primary orthostatic tremor. No severe adverse effects were reported during and after anodal or cathodal tsDCS. Discussion and Conclusions: Although certain studies have found an effect of anodal tsDCS on specific clinical outcomes in people with central nervous system diseases, its effectiveness cannot be established since these findings have not been replicated and the results were heterogeneous. This stimulation was feasible and safe to apply. Further studies are needed to replicate the obtained results of tsDCS when applied in populations with neurological diseases.
- 24 November 2023
- Published by Wolters Kluwer Health in Journal of Neurologic Physical Therapy
- Vol. 48 (2) , 66-74
Trans-Spinal Direct Current Stimulation in Neurological Disorders: A systematic review
Background and Purpose: Trans-spinal direct current stimulation (tsDCS) is a noninvasive stimulation technique that applies direct current stimulation over spinal levels. However, the effectiveness and feasibility of this stimulation are still unclear. This systematic review summarizes the effectiveness of tsDCS in clinical and neurophysiological outcomes in neurological patients, as well as its feasibility and safety. Methods: The search was conducted using the following databases: PEDro, Scopus, Web of Science, CINAHL, SPORTDiscus, and PubMed. The inclusion criteria were: Participants: people with central nervous system diseases; Interventions: tsDCS alone or in combination with locomotion training; Comparators: sham tsDCS, transcranial direct current stimulation, or locomotion training; Outcomes: clinical and neurophysiological measures; and Studies: randomized clinical trials. Results: Eight studies with a total of 143 subjects were included. Anodal tsDCS led to a reduction in hypertonia, neuropathic pain intensity, and balance deficits in people with hereditary spastic paraplegia, multiple sclerosis, and primary orthostatic tremor, respectively. In contrast, cathodal tsDCS only had positive effects on balance and tremor in people with primary orthostatic tremor. No severe adverse effects were reported during and after anodal or cathodal tsDCS. Discussion and Conclusions: Although certain studies have found an effect of anodal tsDCS on specific clinical outcomes in people with central nervous system diseases, its effectiveness cannot be established since these findings have not been replicated and the results were heterogeneous. This stimulation was feasible and safe to apply. Further studies are needed to replicate the obtained results of tsDCS when applied in populations with neurological diseases.
- 18 February 2023
- Published by Elsevier in The Journal of Pain
- Vol. 24 (6) , 946-956
Effectiveness of Different Electrical Stimulation Modalities for Pain and Masticatory Function in Temporomandibular Disorders: A Systematic Review and Meta-Analysis
- 18 February 2023
- Published by Elsevier in The Journal of Pain
- Vol. 24 (6) , 946-956
Effectiveness of Different Electrical Stimulation Modalities for Pain and Masticatory Function in Temporomandibular Disorders: A Systematic Review and Meta-Analysis
- Open Access
- 13 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (4) , 1479
High-Intensity Laser Therapy for Musculoskeletal Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
High-intensity laser therapy (HILT) is one of the therapeutic approaches used in the treatment of musculoskeletal disorders (MSD). The main objective of this study was to examine the effectiveness of HILT for reducing pain and improving functionality in people with MSD. Ten databases were systematically searched for randomized trials published up to 28 February 2022. Randomized clinical trials (RCTs) assessing the effectiveness of HILT on MSD were included. The main outcome measures were pain and functionality. In total, 48 RCTs were included in the qualitative synthesis and 44 RCTs in the quantitative analysis. HILT showed a decrease on the pain VAS (mean difference (MD) = −1.3 cm; confidence interval (CI) 95%: −1.6 to −1.0) and an improvement in functionality (standardized mean difference (SMD) = −1.0; CI95%: −1.4 to −0.7), with low and moderate quality of evidence, respectively. A greater effect was observed when compared with control than with other conservative treatments, both on pain (χ2 = 20.6; p < 0.001) and functionality (χ2 = 5.1; p = 0.02). Differences in the effectiveness of HILT were found depending on the location (χ2 = 40.1 p < 0.001), with further improved functionality in MSD of the knee and shoulder. HILT is an effective treatment for improving pain, functionality, range of motion, and quality of life in people with MSD, although these findings must be treated with caution due to the high risk of bias in the studies. Further clinical trials should be well designed to lower the risk of bias.
- 13 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (4) , 1479
Open AccessHigh-Intensity Laser Therapy for Musculoskeletal Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
High-intensity laser therapy (HILT) is one of the therapeutic approaches used in the treatment of musculoskeletal disorders (MSD). The main objective of this study was to examine the effectiveness of HILT for reducing pain and improving functionality in people with MSD. Ten databases were systematically searched for randomized trials published up to 28 February 2022. Randomized clinical trials (RCTs) assessing the effectiveness of HILT on MSD were included. The main outcome measures were pain and functionality. In total, 48 RCTs were included in the qualitative synthesis and 44 RCTs in the quantitative analysis. HILT showed a decrease on the pain VAS (mean difference (MD) = −1.3 cm; confidence interval (CI) 95%: −1.6 to −1.0) and an improvement in functionality (standardized mean difference (SMD) = −1.0; CI95%: −1.4 to −0.7), with low and moderate quality of evidence, respectively. A greater effect was observed when compared with control than with other conservative treatments, both on pain (χ2 = 20.6; p < 0.001) and functionality (χ2 = 5.1; p = 0.02). Differences in the effectiveness of HILT were found depending on the location (χ2 = 40.1 p < 0.001), with further improved functionality in MSD of the knee and shoulder. HILT is an effective treatment for improving pain, functionality, range of motion, and quality of life in people with MSD, although these findings must be treated with caution due to the high risk of bias in the studies. Further clinical trials should be well designed to lower the risk of bias.
- Open Access
- 9 February 2023
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 17, 1048986
Effect of percutaneous electrical stimulation with high-frequency alternating currents at 30 kHz on the sensory-motor system
Background: Unmodulated high-frequency alternating currents (HFAC) are employed for producing peripheral nerves block. HFAC have been applied in humans with frequencies up to 20 kHz, whether transcutaneously, percutaneously, or via surgically-implanted electrodes. The aim of this study was to assess the effect of percutaneous HFAC, applied with ultrasound-guided needles at 30 kHz, on the sensory-motor nerve conduction of healthy volunteers.Methods: A parallel, double-blind, randomized clinical trial with a placebo control was conducted. Percutaneous HFAC at 30 kHz or sham stimulation was applied via ultrasound-guided needles in 48 healthy volunteers (n = 24 in each group) for 20 min. The assessed outcome variables were pressure pain threshold (PPT), mechanical detection threshold (MDT), maximal finger flexion strength (MFFS), antidromic sensory nerve action potential (SNAP), hand temperature, and subjective sensations by the participants. The measurements were recorded pre-intervention, during the stimulation (at 15 min), immediately post-intervention (at 20 min), and 15 min after the end of treatment.Results: The PPT increased in the active group compared with sham stimulation, both during the intervention [14.7%; 95% confidence interval (CI): 4.4–25.0], immediately post-intervention (16.9%; 95% CI: −7.2–26.5), and 15 min after the end of the stimulation (14.3%; 95% CI: 4.4–24.3) (p < 0.01). The proportion of participants who reported feelings of numbness and heaviness was significantly higher in the active group (46 and 50%, respectively) than in the sham group (8 and 18%, respectively) (p < 0.05). No intergroup differences were observed in the remaining outcome variables. No unexpected adverse effects derived from the electrical stimulation were reported.Conclusion: Percutaneous stimulation with HFAC at 30 kHz applied to the median nerve increased the PPT and subjective perception of numbness and heaviness. Future research should evaluate its potential therapeutic effect in people with pain.Clinical trial registration: https://clinicaltrials.gov/ct2/show/NCT04884932, identifier NCT04884932.
- 9 February 2023
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 17, 1048986
Open AccessEffect of percutaneous electrical stimulation with high-frequency alternating currents at 30 kHz on the sensory-motor system
Background: Unmodulated high-frequency alternating currents (HFAC) are employed for producing peripheral nerves block. HFAC have been applied in humans with frequencies up to 20 kHz, whether transcutaneously, percutaneously, or via surgically-implanted electrodes. The aim of this study was to assess the effect of percutaneous HFAC, applied with ultrasound-guided needles at 30 kHz, on the sensory-motor nerve conduction of healthy volunteers.Methods: A parallel, double-blind, randomized clinical trial with a placebo control was conducted. Percutaneous HFAC at 30 kHz or sham stimulation was applied via ultrasound-guided needles in 48 healthy volunteers (n = 24 in each group) for 20 min. The assessed outcome variables were pressure pain threshold (PPT), mechanical detection threshold (MDT), maximal finger flexion strength (MFFS), antidromic sensory nerve action potential (SNAP), hand temperature, and subjective sensations by the participants. The measurements were recorded pre-intervention, during the stimulation (at 15 min), immediately post-intervention (at 20 min), and 15 min after the end of treatment.Results: The PPT increased in the active group compared with sham stimulation, both during the intervention [14.7%; 95% confidence interval (CI): 4.4–25.0], immediately post-intervention (16.9%; 95% CI: −7.2–26.5), and 15 min after the end of the stimulation (14.3%; 95% CI: 4.4–24.3) (p < 0.01). The proportion of participants who reported feelings of numbness and heaviness was significantly higher in the active group (46 and 50%, respectively) than in the sham group (8 and 18%, respectively) (p < 0.05). No intergroup differences were observed in the remaining outcome variables. No unexpected adverse effects derived from the electrical stimulation were reported.Conclusion: Percutaneous stimulation with HFAC at 30 kHz applied to the median nerve increased the PPT and subjective perception of numbness and heaviness. Future research should evaluate its potential therapeutic effect in people with pain.Clinical trial registration: https://clinicaltrials.gov/ct2/show/NCT04884932, identifier NCT04884932.